Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Behav Brain Res ; 307: 65-72, 2016 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-27036646

RESUMEN

BACKGROUND: Psychiatric disorders are frequently accompanied by changes in brain electrical oscillations and abnormal auditory event related potentials. The goal of this study was to characterize these parameters of a new rat substrain showing several alterations related to schizophrenia. METHODS: Male rats of the new substrain, developed by selective breeding after combined subchronic ketamine treatment and postweaning social isolation, and naive Wistar ones group-housed without any interventions were involved in the present study. At the age of 3 months, animals were implanted with cortical electroencephalography electrodes. Auditory evoked potentials during paired-click stimuli and power of oscillation in different frequency bands were determined with and without acute ketamine (20mg/kg) treatment. RESULTS: Regarding the auditory evoked potentials, the latency of P2 was delayed and the amplitude of N1 peak was lower in the new substrain. The new substrain showed increased power of oscillations in the theta, alpha and beta bands, while decreased power was detected in delta and gamma2 bands (52-70Hz) compared with control animals. Acute ketamine treatment increased the gamma1 band (30-48Hz) power in both groups, while it elicited significant changes only in the new substrain in the total power and in alpha, beta and gamma2 bands. CONCLUSIONS: The validation of the translational utility of this new rat substrain by electrophysiological investigations revealed that these rats show abnormalities that may model a part of the neurophysiological deficits observed in schizophrenia.


Asunto(s)
Electroencefalografía , Potenciales Evocados Auditivos/fisiología , Esquizofrenia/fisiopatología , Estimulación Acústica , Factores de Edad , Animales , Modelos Animales de Enfermedad , Antagonistas de Aminoácidos Excitadores/toxicidad , Femenino , Análisis de Fourier , Ketamina/toxicidad , Locomoción/efectos de los fármacos , Locomoción/fisiología , Masculino , Ratas , Ratas Wistar , Esquizofrenia/etiología , Aislamiento Social/psicología
2.
Behav Brain Res ; 240: 134-45, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23195116

RESUMEN

Gene-environment interactions have an important role in the development of psychiatric disorders. To generate and validate a new substrain of rats with signs related to schizophrenia, we used selective breeding after postweaning social isolation and chronic ketamine treatment through several generations of animals and compared the subsequent strain to naive rats that were not genetically manipulated. We further investigated whether social isolation and ketamine treatment augmented the appearance of schizophrenic-like signs in these rats. Four experimental groups were studied (n=6-15 rats/group): naive rats without any treatment (NaNo); naive rats with postweaning social isolation and ketamine treatment (NaTr); 15th generation of selectively bred animals without any treatment (SelNo) or selectively bred rats with both isolation and ketamine treatment (SelTr). The startle reaction, tail-flick and novel object recognition tests were used to classify the animals into low- or high-risk for schizophrenia. Reduced pain sensitivity, higher degree of the startle reaction, disturbed prepulse inhibition, altered motor activity and decreased differentiation index in the memory test were observed in the 15th generation of the substrain, along with enhanced grooming behavior. Five functional indices (TF latency, startle reaction, prepulse inhibition, differentiation index, and grooming activity) were rated from 0 to 2, and the analysis of the summarized score revealed that the NaNo group had the lowest overall indication of schizophrenic-like signs, while the SelTr animals scored the highest, suggesting that both heritable and environmental factors were important in the generation of the behavioral alterations. We assume that further breeding after this complex treatment may lead to a valid and reliable animal model of schizophrenia.


Asunto(s)
Conducta Animal/efectos de los fármacos , Interacción Gen-Ambiente , Ketamina/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Reflejo de Sobresalto/efectos de los fármacos , Esquizofrenia/genética , Aislamiento Social , Estimulación Acústica , Animales , Conducta Animal/fisiología , Cruzamiento/métodos , Modelos Animales de Enfermedad , Predisposición Genética a la Enfermedad , Masculino , Umbral del Dolor/efectos de los fármacos , Umbral del Dolor/fisiología , Ratas , Reflejo de Sobresalto/genética , Esquizofrenia/etiología
3.
Clin Exp Pharmacol Physiol ; 36(4): 400-5, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19018802

RESUMEN

1. Although it is well known that the combined administration of synthetic or plant-originated opioids with cannabinoids (CB) results in synergistic antinociception, the effects of combined administration of endogenous ligands acting at micro-opioid and CB receptors are not known. The aim of the present study was to determine the interaction between anandamide (AEA; a CB(1) receptor agonist) and endomorphin-1 (EM-1; a micro-opioid receptor agonist) after intrathecal administration. 2. Nociception was assessed by the paw-withdrawal test after carrageenan-induced inflammation in male Wistar rats. 3. Endomorphin-1 (16.4 pmol to 16.4 nmol) and AEA (4.3-288 nmol) alone dose-dependently decreased carrageenan-induced thermal hyperalgesia, although the highest dose of AEA also exhibited pain-inducing potential. The potency of AEA was approximately 59-fold lower than that of EM-1 (35% effective dose (ED(35)) 194.4 vs 3.3 nmol, respectively). Coadministration of these ligands revealed that combinations of 16.4 pmol EM-1 plus 28.8 or 86.5 nmol AEA were more effective than either drug alone, but other combinations were no more effective than the administration of EM-1 itself. Therefore, coadministration of AEA did not significantly shift the dose-response curve to EM-1. 4. The results of the present study indicate that the coadministration of AEA and EM-1 results in potentiated antihyperalgesia only for a combination of specific doses. Because AEA activates other receptor types (e.g. TRPV1) in addition to CB(1) receptors, the results of the present suggest that, after the coadministration of EM-1 and AEA, complex interactions ensue that may lead to different outcomes compared with those seen following the injection of exogenous ligands.


Asunto(s)
Ácidos Araquidónicos/farmacología , Hiperalgesia/tratamiento farmacológico , Oligopéptidos/farmacología , Alcamidas Poliinsaturadas/farmacología , Columna Vertebral , Analgésicos/administración & dosificación , Analgésicos/farmacología , Animales , Ácidos Araquidónicos/administración & dosificación , Carragenina , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Endocannabinoides , Hiperalgesia/inducido químicamente , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inyecciones Espinales , Masculino , Oligopéptidos/administración & dosificación , Dolor/inducido químicamente , Dolor/tratamiento farmacológico , Dolor/metabolismo , Alcamidas Poliinsaturadas/administración & dosificación , Ratas , Ratas Wistar , Columna Vertebral/efectos de los fármacos , Columna Vertebral/metabolismo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA